12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclizumab: Additional Phase II data

Additional data from the double-blind, international Phase II CHOICE study showed that a subset of 23 patients (12%) with neutralizing antibodies against interferon (IFN) beta had significantly fewer new or enlarged lesions when treated with 1 or 2 mg/kg daclizumab plus IFN beta vs. placebo...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >